Aggamin is a bio-medical company founded by a scientific and business team in early 2010 to develop and commercialize therapies for a variety of diseases.  The lead program is focused on preeclampsia — a currently untreatable disease effecting 10% of pregnancies with an annual cost to the U.S health care system of $7 billion.  The Company employs technologies in an innovative, proprietary, low-risk platform strategy to accelerate the drug development path.  Our goal is to rapidly develop therapies to proprietary targets to improve patient health and quality of life.

< Back to Portfolio